The stock of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is a huge mover today! About 3.25 million shares traded hands. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has risen 104.82% since March 4, 2016 and is uptrending. It has outperformed by 96.78% the S&P500.
The move comes after 9 months negative chart setup for the $179.97 million company. It was reported on Oct, 7 by Barchart.com. We have $4.29 PT which if reached, will make NASDAQ:AUPH worth $21.60M less.
Analysts await Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to report earnings on November, 11. They expect $-0.14 EPS, up 22.22% or $0.04 from last year’s $-0.18 per share. After $-0.14 actual EPS reported by Aurinia Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.”
More important recent Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) news were published by: Nasdaq.com which released: “Mid-Day Market Update: Aurinia Pharmaceuticals Gains On AURION Data; Twitter …” on October 06, 2016, also Investorplace.com published article titled: “Aurinia Pharmaceuticals Inc (AUPH) Makes Comeback on Encouraging Trial Data”, 247Wallst.com published: “Aurinia Pharma Skyrockets on Positive Data From Lupus Study” on October 06, 2016. More interesting news about Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) was released by: Businesswire.com and their article: “Aurinia Pharmaceuticals to Present at the 2016 Rodman & Renshaw 18 th Annual …” with publication date: September 07, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.